BiotechTube

Idebenone + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

Apr 1, 2011 โ†’ Jul 1, 2012

NCT ID
NCT01303406

About Idebenone + Placebo

Idebenone + Placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT01303406. Target conditions include Friedreich's Ataxia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (5)

NCT IDPhaseStatus
NCT01495715Phase 3Withdrawn
NCT01303406Phase 3Completed
NCT00747487Phase 2Completed
NCT00905268Phase 3Completed
NCT00654784Phase 2Completed

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors
ProductCompanyStageHype Score
Interferon ฮณ-1bAmgenPhase 3
76
interferon ฮณ-1bAmgenPhase 3
76
Interferon ฮณ-1b + PlaceboAmgenPhase 3
76
varenicline + placeboPfizerPhase 2/3
64
Lu AA24493 + PlaceboLundbeckPhase 2
49
OmeveloxoloneBiogenPre-clinical
20
Placebo + EPI-743 400 mg + EPI-743 200 mgPTC TherapeuticsPhase 2
49
SGT-212Solid BiosciencesPhase 1
25
idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
IdebenoneSanthera PharmaceuticalsPhase 3
69

Other Products from Santhera Pharmaceuticals

vamorolone 40 mg/mL oral suspensionApproved
77
IdebenoneApproved
77
Placebo + IdebenonePhase 3
69
idebenonePhase 3
69
idebenone + PlaceboPhase 3
69